These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23594867)

  • 1. [Individualized dosing guidelines for children].
    Knibbe CA; Tibboel D; de Wildt SN; de Hoog M; Tjoeng MM; Danhof M
    Ned Tijdschr Geneeskd; 2013; 157(16):A4214. PubMed ID: 23594867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.
    Bartelink IH; Rademaker CM; Schobben AF; van den Anker JN
    Clin Pharmacokinet; 2006; 45(11):1077-97. PubMed ID: 17048973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding dosing: children are small adults, neonates are immature children.
    Anderson BJ; Holford NH
    Arch Dis Child; 2013 Sep; 98(9):737-44. PubMed ID: 23832061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A unified pharmacokinetic approach to individualized drug dosing.
    Begg EJ; Chin PK
    Br J Clin Pharmacol; 2012 Mar; 73(3):335-9. PubMed ID: 21851378
    [No Abstract]   [Full Text] [Related]  

  • 5. Inconsistencies in dosage practice in children with overweight or obesity: A retrospective cohort study.
    Gade C; Christensen HR; Dalhoff KP; Holm JC; Holst H
    Pharmacol Res Perspect; 2018 Jun; 6(3):e00398. PubMed ID: 29721323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosing dilemmas in obese children.
    Mulla H; Johnson TN
    Arch Dis Child Educ Pract Ed; 2010 Aug; 95(4):112-7. PubMed ID: 20585055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric Obesity: Pharmacokinetics and Implications for Drug Dosing.
    Kendrick JG; Carr RR; Ensom MH
    Clin Ther; 2015 Sep; 37(9):1897-923. PubMed ID: 26361823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PK-DB: pharmacokinetics database for individualized and stratified computational modeling.
    Grzegorzewski J; Brandhorst J; Green K; Eleftheriadou D; Duport Y; Barthorscht F; Köller A; Ke DYJ; De Angelis S; König M
    Nucleic Acids Res; 2021 Jan; 49(D1):D1358-D1364. PubMed ID: 33151297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Dosing in Obese Children: Challenges and Evidence-Based Strategies.
    Xiong Y; Fukuda T; Knibbe CAJ; Vinks AA
    Pediatr Clin North Am; 2017 Dec; 64(6):1417-1438. PubMed ID: 29173794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic- and pharmacodynamic-based antithrombotic dosing recommendations in children.
    Ko RH; Young G
    Expert Rev Clin Pharmacol; 2012 Jul; 5(4):389-96. PubMed ID: 22943118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults.
    Pai MP
    Pharmacotherapy; 2012 Sep; 32(9):856-68. PubMed ID: 22711238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualizing dosing of irinotecan.
    Ratain MJ; Innocenti F
    Clin Cancer Res; 2010 Jan; 16(2):371-2. PubMed ID: 20068075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient impact of automated glomerular filtration rate reporting on drug dosing for hospitalized older adults with concealed renal insufficiency.
    Kalender-Rich JL; Mahnken JD; Wetmore JB; Rigler SK
    Am J Geriatr Pharmacother; 2011 Oct; 9(5):320-7. PubMed ID: 21920825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuities and disruptions in drug dosage guidelines for the paediatric population.
    Chitty KM; Chan B; Pulanco CL; Luu S; Egunsola O; Buckley NA
    Br J Clin Pharmacol; 2018 May; 84(5):1029-1037. PubMed ID: 29411410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ontogeny of Drug-Metabolizing Enzymes.
    Thakur A; Parvez MM; Leeder JS; Prasad B
    Methods Mol Biol; 2021; 2342():551-593. PubMed ID: 34272706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and evaluation of a generic physiologically based pharmacokinetic model for children.
    Edginton AN; Schmitt W; Willmann S
    Clin Pharmacokinet; 2006; 45(10):1013-34. PubMed ID: 16984214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Status Toward the Implementation of Precision Dosing in Children.
    Barrett JS; Barrett RF; Vinks AA
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S36-S51. PubMed ID: 34185896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualized dosing regimens in children based on population PKPD modelling: are we ready for it?
    Knibbe CA; Danhof M
    Int J Pharm; 2011 Aug; 415(1-2):9-14. PubMed ID: 21376791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.